Neurotype Inc.
Duluth, MN
- UEI
- CKJEWEVBWP54
- CAGE
- 8DPW2
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 624 E 1st St #301, Duluth, MN 55805, USA
- Website
- neurotype.io
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Regents Of The University Of Minnesota | UG3DA059414 | $105,832 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Q2I LLC | Rindge, NH | — |
| Highland Instruments Inc. | Braintree, MA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Epivario Inc. | Philadelphia, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Mountain Manor Baltimore | Baltimore, MD | 623220 Residential Mental Health and Substance Abuse Facilities |
| Evon Medics LLC | Ellicott City, MD | — |
About the company
Neurotype Inc. is a for-profit organization registered to receive federal grants and contracts. It provides neurological and neuroscience-based solutions, with a focus on developing devices and software to monitor and treat substance use disorders, particularly opioid use disorder (OUD).
Through federal grants from agencies like the National Institute on Drug Abuse (NIDA), Neurotype has developed portable neurotherapeutic devices integrating electroencephalogram (EEG) technology and neurofeedback mechanisms to monitor and modify neural processes underlying opioid cravings and drug-seeking behavior. Notable projects include developing a regulated EEG-based device to quantify brain responses to opioid cues for assessing cue-induced craving biomarkers, and MODIT-AB, a closed-loop neurofeedback system using attention bias modification to reduce opioid cravings. Neurotype has also received grants for mobile brain sensing platforms to detect opioid cravings and treatment responses. Additionally, it has collaborated as a sub-grantee with the University of Minnesota on digital cognitive behavioral therapy interventions for OUD with co-occurring internalizing disorders. Neurotype's work spans product development, clinical trials, regulatory submissions, and commercial feasibility assessments for its neurological solutions targeting addiction treatment.
Quick answers
Is Neurotype Inc. registered in SAM.gov?
Yes. Neurotype Inc.'s SAM.gov registration is active through September 18, 2027.
What is Neurotype Inc.'s most recent federal award?
Neurotype Inc.'s most recent federal grant award is CUE-induced drug craving monitoring for opioid use disorder with visual evoked potentials (R44DA059517), from National Institute on Drug Abuse (NIH), on September 30, 2023.
On GovTribe
See Neurotype Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors